LSE · AZN.L
AstraZeneca PLC
£139.60+£9.08 (+6.96%)
AstraZeneca PLC’s quoted price sits in the upper half of its reported 52-week range, 11.26% below the high.
Loading market information…
OTC · BHCCF · USD
Stock price, earnings
Quote as of Oct 29, 2026, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Benchmark Holdings plc’s quoted price sits in the lower half of its reported 52-week range, 7.72% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Benchmark Holdings plc’s next earnings report is currently expected on Dec 2, 2026. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Benchmark Holdings plc’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Benchmark Holdings plc is dedicated to empowering the food and agriculture sectors by furnishing specialized knowledge, services, and products. The company's operations are divided into three core divisions: Genetics, Advanced Nutrition, and Health. Within its Genetics arm, Benchmark provides cutting-edge breeding technologies and facilities for species such as sea bass/bream, salmon, shrimp, and tilapia, delivering genetically superior ova. The Advanced Nutrition division focuses on creating and supplying vital nutritional and health products specifically for the aquaculture industry. Meanwhile, the Health segment offers crucial medicinal solutions for the aquaculture market, including treatments like Ectosan Vet and CleanTreat for sea lice. Founded in 2000 and headquartered in Sheffield, United Kingdom, Benchmark Holdings plc maintains a broad international presence, conducting business in diverse regions including the UK, Norway, the Faroe Islands, Ecuador, India, Greece, Singapore, Chile, Turkey, other European countries, and worldwide.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 07:31 PM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| Q2 2024 | May 22, 2024 | -$0.00-140.36% vs estimate | $49.89M-14.08% vs estimate |
|---|
| Q1 2024 | Feb 15, 2024 | -$0.01-384.72% vs estimate | $51.16M-18.26% vs estimate |
|---|
| Q4 2023 | Sep 30, 2023 | -$0.02-175.91% vs estimate | $44.21M-13.26% vs estimate |
|---|
THE ANALYST VIEW
1 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
£139.60+£9.08 (+6.96%)
AstraZeneca PLC’s quoted price sits in the upper half of its reported 52-week range, 11.26% below the high.
£18.55+£0.41 (+2.26%)
GSK plc’s quoted price sits in the lower half of its reported 52-week range, 18.71% below the high.
€9.97-€0.46 (-4.41%)
Emeis’s quoted price sits in the lower half of its reported 52-week range, 37.69% below the high.
$6.52+$0.15 (+2.35%)
Silence Therapeutics plc’s quoted price sits in the upper half of its reported 52-week range, 0.0% below the high.
CA$12.90-CA$0.60 (-4.44%)
Cipher Pharmaceuticals Inc.’s quoted price sits in the lower half of its reported 52-week range, 37.26% below the high.
€0.73+€0.00 (+0.41%)
Transgene S.A.’s quoted price sits in the lower half of its reported 52-week range, 51.6% below the high.
A$2.54+A$0.04 (+1.6%)
Mayne Pharma Group Limited’s quoted price sits in the lower half of its reported 52-week range, 57.95% below the high.
$0.00$0.00 (0.0%)
China Evergrande New Energy Vehicle Group Limited’s quoted price sits in the upper half of its reported 52-week range, 0.0% below the high.
